Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 3/20 | 0.50 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | MAPK15 | Q8TD08 | 1/20 | 0.45 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.44 |
| ▸ | SYK | P43405 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | SGK1 | O00141 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | ROS1 | P08922 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31664180 | 0.89 | EGFR (0.48) | PTK2LRRK2PIK3CGEGFRMET | |
| SCHEMBL602789 | 0.89 | EGFR (0.48) | PTK2LRRK2PIK3CGEGFRMET | |
| SCHEMBL1707277 | 0.87 | ZAP70 (0.46) | PTK2PIK3CGEGFRPTGS1PTGS2 | |
| SCHEMBL26906847 | 0.84 | EGFR (0.48) | PTK2LRRK2PIK3CGEGFRMET | |
| SCHEMBL30659886 | 0.84 | EGFR (0.48) | PTK2LRRK2PIK3CGEGFRMET | |
| SCHEMBL1707715 | 0.83 | PTK2 (0.58) | GLO1PTK2GSK3ALRRK2MAPK15 | |
| SCHEMBL30942603 | 0.82 | GLO1 (0.69) | GLO1PTK2GSK3ALRRK2MAPK15 | |
| SCHEMBL542074 | 0.82 | GLO1 (0.69) | GLO1PTK2GSK3ALRRK2MAPK15 | |
| SCHEMBL1706914 | 0.81 | PTK2 (0.58) | GLO1PTK2GSK3ALRRK2MAPK15 | |
| SCHEMBL4823621 | 0.81 | GAA (0.58) | PTK2SYKAURKAALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172385-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20120172385-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20120172385-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20120142667-A1 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| EP-2440534-A2 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | Cellzome Limited (GB) | 2012-04-18 | — | — | EP | disclosed |
| EP-2419423-A1 | FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS | Cellzome Limited (GB) | 2012-02-22 | — | — | EP | disclosed |
| US-20120040955-A1 | FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS | CELLZOME LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120040955-A1 | FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS | CELLZOME LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120040955-A1 | FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS | CELLZOME LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| WO-2011029807-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-03-17 | — | — | WO | disclosed |
| WO-2010142766-A2 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010118986-A1 | FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS | CELLZOME LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010118986-A1 | FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS | CELLZOME LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142667-A1 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | ZAP70, LCK, DPY30 | GLO1 4299/4885PTK2 1584/4885GSK3A 1621/4885 |
| US-20120040955-A1 | FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | GLO1 3765/4885PTK2 492/4885GSK3A 744/4885 |
| US-20120172385-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | JAK3, JAK1, JAK2 | GLO1 4285/4885PTK2 657/4885GSK3A 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.